{"id":44448,"date":"2014-08-04T16:54:25","date_gmt":"2014-08-04T20:54:25","guid":{"rendered":"http:\/\/blogs.nejm.org\/cardioexchange\/?post_type=voices&#038;p=44448"},"modified":"2014-08-04T16:54:25","modified_gmt":"2014-08-04T20:54:25","slug":"selections-from-richard-lehmans-literature-review-august-4th","status":"publish","type":"post","link":"https:\/\/blogs.nejm.org\/cardioexchange\/2014\/08\/04\/selections-from-richard-lehmans-literature-review-august-4th\/","title":{"rendered":"Selections from Richard Lehman\u2019s Literature Review: August 4th"},"content":{"rendered":"<p><em>CardioExchange is pleased to reprint this selection from Dr. Richard Lehman\u2019s\u00a0<a href=\"http:\/\/blogs.bmj.com\/bmj\/category\/richard-lehmans-weekly-review-of-medical-journals\/\" target=\"_blank\">weekly journal review blog<\/a>\u00a0at\u00a0<a href=\"http:\/\/www.bmj.com\/\">BMJ.com<\/a>. Selected summaries are relevant to our audience, but we encourage members to engage with the\u00a0<a title=\"Lehman_8282012\" href=\"http:\/\/blogs.bmj.com\/bmj\/2014\/08\/04\/richard-lehmans-journal-review-4-august-2014\/\" target=\"_blank\">entire blog<\/a>.<\/em><\/p>\n<p><strong><em>JAMA Intern Med<\/em> August 2014<\/strong><\/p>\n<p><strong>Trends in Use of Ezetimibe After the ENHANCE Trial (OL):<\/strong>\u00a0 Once more it is time to praise Joe Ross. He has two articles waiting to see print in <em>JAMA Internal<\/em>. The first one <a href=\"http:\/\/archinte.jamanetwork.com\/article.aspx?articleid=1890286\">tracks the continuing use of ezetimibe in the United States<\/a> following the ENHANCE trial, which demonstrated that ezetimibe use lowered cholesterol levels, but did not slow the progression of atherosclerosis. He and his team looked at the records of 10\u2009597\u2009296 continuously eligible adults in the USA, and found that nearly three years after ezetimibe had been shown to do nothing, 186\u2009272 of them were still ezetimibe users, i.e. 1.8% of the total adult population.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>This week&#8217;s topic is on the trends in use of ezetimibe after the ENHANCE trial.<\/p>\n","protected":false},"author":475,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[2325,577],"class_list":["post-44448","post","type-post","status-publish","format-standard","hentry","category-general","tag-enhance","tag-ezetimibe"],"_links":{"self":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/44448","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/users\/475"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/comments?post=44448"}],"version-history":[{"count":0,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/44448\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/media?parent=44448"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/categories?post=44448"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/tags?post=44448"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}